On the evening of December 19, China Pharmaceutical (600056), which hit the daily limit for three consecutive days, issued a risk warning announcement for the second time within three days.
In this risk warning, China Pharmaceutical made it clear that as of the end of November this year, preliminary statistics on the sales scale of the new coronavirus treatment drug Paxlovid accounted for less than 1.5% of the company's operating income in the first three quarters, which did not have a significant impact on the company's current operating performance.
agent Paxlovid sales are below 400 million
China Pharmaceutical (600056) This round of stock price abnormal movement began on December 15. The day before, China Pharmaceutical announced that it had once again signed an agreement with Pfizer , which will be responsible for the import and distribution of Pfizer's new coronavirus treatment drug Nematvir tablets/ritonavir tablets (Paxlovid) in the mainland Chinese market from December 14, 2022 to November 30, 2023.
From December 15th to the present, China Pharmaceutical has repeatedly emphasized through multiple channels such as announcements and media interviews that this matter is expected to have no significant impact on the company's operating performance. However, this did not change the stock price soaring trend. Since December 15th, China Pharmaceutical, with a market value of about 25 billion yuan, has hit the daily limit for three consecutive trading days. As of the closing on the 19th, China Pharmaceutical's market value has reached 33.4 billion yuan, and its market value has risen by about 8.4 billion yuan in three trading days.
On December 19, China Pharmaceutical once again disclosed a risk warning announcement, clarifying that as of the end of November 2022, preliminary statistics were made that the sales scale of Paxlovid's business accounted for less than 1.5% of the company's operating income in the first three quarters, which did not have a significant impact on the company's current operating performance.
According to China Pharmaceutical's third quarter report, the company's operating income in the first three quarters was 26.917 billion yuan. According to the Chinese pharmaceutical expression, Pfizer Paxlovid's sales in the mainland Chinese market are below 400 million yuan.
On the one hand, as a strategic reserve and procurement unit of the state-designated drug and medical protective materials, China Pharmaceutical stated that it will "strive to practice the political responsibility of state-owned central enterprises and the social responsibility of "; on the other hand, China Pharmaceutical stated that Paxlovid has been temporarily included in the payment scope of medical insurance fund in various provinces, "it is purchased by medical institutions at prices consistent with the communication between the enterprises and relevant departments." China Pharmaceutical once again emphasized that there is great uncertainty in the sales of products due to factors such as the epidemic, distribution and terminal final use.
Paxlovid perturbs market nerves
But anyway, Paxlovid does have the ability to perturb market nerves.
As a scarce oral drug for COVID-19, Paxlovid's sales performance in overseas was amazing. According to Pfizer's financial report, its sales of Paxlovid reached US$7.514 billion in the third quarter. In the first three quarters of this year, Pfizer 's oral drug revenue reached US$17.199 billion. Pfizer said that the new crown oral medicine has performed well in the United States and the company will continue to develop towards the goal of increasing revenue by US$25 billion by 2030.
In March this year, China Pharmaceutical rose 230% in a single month. The reason for the surge was also due to the company signing an agreement with Pfizer to carry out Paxlovid's commercial operations in the mainland. China Pharmaceutical disclosed ten risk warning announcements that month, but it also failed to prevent the company's stock price from soaring.
. In this round of market in December, although China Pharmaceutical hit the daily limit again on the 19th, it had released nearly 7 billion yuan of daily volume of during the session, and the turnover rate of is about 21%.
Dragon Tiger List data shows that on December 19, China's pharmaceutical buying funds were more concentrated than selling funds. Among them, northbound funds ranked first and first seats at the same time, with the purchase and sale amounts of RMB 196 million and RMB 82.6266 million respectively, and net purchase of was about RMB 113 million. Buy 2 and 3 seats, Huatai Securities Headquarters and Guotai Junan Nanjing Taiping South Road, respectively, bought 135 million yuan and 90.865 million yuan. The seller's second to fourth seats sold the amount of 60 million yuan was sold at Xi'an Zhuque Street, Dongfang Fortune Mountain Nanxiangqu East Road, and Guosheng Securities Ningbo Sangtian Road.
column editor: Qin Hong Text editor: Cheng Pei Title image source: Visual China Picture editor: Cao Liyuan
Source: Author: Securities Times Zhang Yifan
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-